• Targeted Non-Viral Gene Delivery to Adipocytes via ATS-9R

  2026-05-02

  This study establishes a fusion oligopeptide, ATS-9R, as a highly specific, non-viral gene delivery vehicle for mature adipocytes. By leveraging prohibitin-mediated endocytosis, ATS-9R enables efficient gene silencing and metabolic improvement in obesity models, representing a significant advance for targeted metabolic research.

• Tropifexor (LJN452) Restores Intestinal Barrier in PN-Fed Pi

  2026-05-01

  This study demonstrates that the FXR agonist Tropifexor (LJN452) significantly mitigates intestinal injury and improves epithelial barrier integrity in neonatal piglets receiving parenteral nutrition. The findings introduce a potential strategy for protecting vulnerable pediatric patients from PN-associated complications through targeted FXR modulation.

• Mechanism-Centric Discovery of M. tuberculosis DHFR Inhibito

  2026-04-30

  Santa Maria et al. introduce a machine learning-guided framework integrating high-throughput binding and phenotypic screens to identify Mycobacterium tuberculosis dihydrofolate reductase (DHFR) inhibitors. This innovation advances antibacterial research by connecting compound bioactivity to molecular targets, enabling more precise development of antibiotics against resistant pathogens.

• WP1066: Mechanistic and Strategic Advances in JAK2/STAT3 Res

  2026-04-30

  This thought-leadership article from APExBIO’s scientific marketing team explores the dual mechanistic and translational impact of WP1066, a cell-permeable JAK2/STAT3 inhibitor, for researchers targeting cancer, hematologic malignancies, and emerging immunoregenerative contexts. By weaving together recent mechanistic insights—including the pivotal role of JAK2-STAT3 in both oncology and infectious bone defect repair—this piece provides both strategic guidance and practical parameters, situating WP1066 as a catalyst for the next wave of translational breakthroughs.

• Cytarabine (AraC): Precision Targeting of DNA Damage and Apo

  2026-04-29

  Explore how Cytarabine (AraC) enables advanced mechanistic studies in DNA damage response and apoptosis, with a unique focus on kinase activation, resistance mechanisms, and viral modulation of cell death pathways. Discover how this nucleoside analog informs leukemia research and apoptosis pathway interrogation.

• SU5416 (Semaxanib): Precision Angiogenesis Inhibition for Ad

  2026-04-29

  Explore SU5416 (Semaxanib), a highly selective VEGFR2 inhibitor, in the context of vascular and immunometabolic research. This article uniquely dissects its mechanistic nuances, solubility challenges, and cross-talk with emerging HIF1α metabolic pathways, delivering actionable guidance for advanced experimental applications.

• Metoprolol Tartrate: Precision β1 Blockade for Translational

  2026-04-28

  This thought-leadership article offers translational researchers an advanced, mechanistic perspective on Metoprolol Tartrate—a selective β1-adrenergic blocking agent—bridging cardiovascular and hematopoietic research. By integrating recent evidence distinguishing β1-selective versus nonselective β-blockade in hematopoietic regeneration, it provides strategic guidance for experimental design, protocol optimization, and clinical translation. This article escalates the discourse beyond standard product pages by synthesizing biological rationale, experimental validation, and workflow-centric recommendations, while directly referencing APExBIO’s high-purity Metoprolol Tartrate and linking to related thought-leadership resources.

• Optimizing Dye Use for Small Tissue Biopsies in Pathology La

  2026-04-28

  This article examines recent evidence on the effectiveness of various tissue marking dyes for improving the visibility and retention of small tissue biopsies during histological processing. The referenced study identifies hematoxylin as a preferred marking dye due to its low toxicity and minimal interference with diagnostic evaluation, with implications for workflow optimization in surgical pathology.

• PTGER4 Signaling Modulates HDAC Activity and SPINK4 in Recta

  2026-04-27

  Anbazhagan et al. (2024) reveal that PTGER4 signaling in rectal epithelial cells controls class IIa HDAC phosphorylation and SPINK4 mRNA levels, providing mechanistic insight into mucosal homeostasis and injury response. Their findings clarify how PGE2-driven PTGER4 activation by mesenchymal stromal cells orchestrates epithelial gene regulation and protein release, informing both basic research and translational strategies in gastrointestinal disease.

• Regulatory Gene Engineering Boosts A40926 Antibiotic Product

  2026-04-27

  This study demonstrates that heterologous expression of distant StrR-like regulatory genes, specifically chers28, can significantly enhance the production of the glycopeptide antibiotic A40926 in Nonomuraea gerenzanensis. These findings open new avenues for optimizing antibiotic yields through cross-pathway regulatory engineering, with implications for both basic research and industrial biosynthesis.

• Dihydroartemisinin: Mechanistic Leverage in Translational Sc

  2026-04-26

  Dihydroartemisinin (DHA), an Artemisia plant extract and potent mTOR signaling pathway inhibitor, is redefining translational strategies in malaria, inflammation, and cell proliferation research. This article delivers mechanistic clarity, protocol recommendations, and critical insights for researchers aiming to bridge preclinical promise with actionable workflows, while positioning APExBIO’s high-purity DHA as a benchmark compound.

• 3-Methyladenine (SKU A8353): Workflow Solutions for Autophag

  2026-04-25

  This article delivers scenario-driven, evidence-based guidance for researchers using 3-Methyladenine (SKU A8353) in autophagy, viability, and cytotoxicity assays. By addressing common laboratory challenges and integrating recent literature, it demonstrates how 3-Methyladenine streamlines experimental workflows and supports reproducibility in demanding cell biology studies.

• LNP-Delivered miR-200c Targets Pancreatic Cancer via Dual Pa

  2026-04-24

  Yu et al. (2025) demonstrate that lipid nanoparticle (LNP)-enclosed miR-200c exerts potent anti-tumor effects in pancreatic cancer by simultaneously activating the PTPN6 enhancer and repressing CDH17 expression. This dual mechanism highlights NamiRNA's therapeutic potential and offers evidence for enhancer-targeted RNA therapeutics in highly aggressive malignancies.

• MCL-1’s Anti-Apoptotic Role in Breast Cancer: Mechanistic Ev

  2026-04-24

  This study establishes that breast cancer cell dependence on MCL-1 is rooted in its canonical anti-apoptotic activity, rather than non-apoptotic roles. Genetic deletion or targeted inhibition of MCL-1 impedes tumor growth, contingent on the presence of pro-apoptotic proteins BAX and BAK, highlighting MCL-1 as a precise target for apoptosis-based interventions in breast cancer.

• Deracoxib in Translational Cancer and Inflammation Models

  2026-04-23

  Explore how Deracoxib, a selective COX-2 inhibitor, advances pain and inflammation research and cancer biology with unique cell-specific and mechanism-driven effects. This article delivers rigorous scientific depth and practical insights not found in current literature.

457 records 20/31 page Previous Next First page 上5页 1617181920 下5页 Last page